Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Hideto Akama"'
Autor:
Tomoo Fukuda, Keiko Yamagami, Kimito Kawahata, Yuzo Suzuki, Yoshihiro Sasaki, Takashi Miyagi, Iris Jacobs, John-Philip Lawo, Fiona Glassman, Hideto Akama, Michihiro Hide, Isao Ohsawa
Publikováno v:
Allergology International, Vol 72, Iss 3, Pp 451-457 (2023)
Background: Hereditary angioedema (HAE) is a rare and potentially life-threatening genetic disorder characterized by recurrent attacks of angioedema. HAE types I and II result from deficient or dysfunctional C1-esterase inhibitor (C1–INH). This Pha
Externí odkaz:
https://doaj.org/article/41fb99ae42094f549215fbbd33660195
Autor:
Fiona Glassman, Summer Goodson, Alex Bica, Anthony Roberts, Hideto Akama, Yumiko Asami, Meena Jain, Milin Acharya
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d5bdfa9afd7a8f0bca16ebb565b969
https://doi.org/10.1016/j.jaci.2022.12.448
https://doi.org/10.1016/j.jaci.2022.12.448
Autor:
Shunji Matsuki, Maiko Nomoto, Seiichiro Hojo, Hideto Akama, Kyoko Matsuguma, Fuminori Ohba, Shuhei Imayama
Publikováno v:
Journal of Dermatological Treatment. 27:467-472
Phosphodiesterase type 4 (PDE4) inhibition is a well-known anti-inflammatory mechanism. However, the clinical use of PDE4 inhibitors has been compromised by the occurrence of mechanism-associated adverse reactions, which often limit the maximum toler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09fa0ca6125dd331f67a92d0fc30a355
https://doi.org/10.3109/09546634.2016.1157257
https://doi.org/10.3109/09546634.2016.1157257
Publikováno v:
Journal of Dermatological Treatment. 27:241-246
The purpose of the present studies was to assess the safety, tolerability and pharmacokinetics of topical application of a novel phosphodiesterase inhibitor, E6005, in healthy volunteers and in patients with atopic dermatitis (AD).In two randomized,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2b17e6a5ddc3485e306ca1f4312a2ae
https://doi.org/10.3109/09546634.2015.1093587
https://doi.org/10.3109/09546634.2015.1093587
Autor:
Masutaka, Furue, Yasumi, Kitahara, Hideto, Akama, Seiichiro, Hojo, Nobukazu, Hayashi, Hidemi, Nakagawa, Satoshi, Takeuchi
Publikováno v:
The Journal of Dermatology. 41:577-585
The safety and efficacy of topical E6005, a novel phosphodiesterase 4 inhibitor, in Japanese adults with atopic dermatitis were evaluated. A total of 78 patients were randomized to receive either the 0.2% E6005 ointment or vehicle control (without E6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f578a2ae1120190c1cbd62cd6662d91
https://doi.org/10.1111/1346-8138.12534
https://doi.org/10.1111/1346-8138.12534
Autor:
Shoji Uchida, Hideto Akama, Vipin Arora, Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Tsukasa Matsubara, Nobuyuki Miyasaka, Masaya Mukai, Naoki Ishiguro, Hartmut Kupper
Publikováno v:
Rheumatology (Oxford, England)
Objective. The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity. Methods.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d31a7eb76b5e9f093b79c04a5a8b5d70
https://doi.org/10.1093/rheumatology/ket465
https://doi.org/10.1093/rheumatology/ket465
Autor:
Shoji Uchida, Yoshiya Tanaka, Hartmut Kupper, Masaya Mukai, Nobuyuki Miyasaka, Hideto Akama, Hisashi Yamanaka, Tsukasa Matsubara, Vipin Arora, Tsutomu Takeuchi, Naoki Ishiguro
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo evaluate the efficacy and safety of adalimumab+methotrexate (MTX) in Japanese patients with early rheumatoid arthritis (RA) who had not previously received MTX or biologics.MethodsThis randomised, double-blind, placebo-controlled, multic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d4f5be15ebd7e7d7c5b17d39452c03d
http://europepmc.org/articles/PMC4151516
http://europepmc.org/articles/PMC4151516
Autor:
Hideto Akama
Publikováno v:
Japanese Journal of Clinical Immunology. 34:464-475
Glucocorticoids (steroids) have been widely used for the treatment of patients with rheumatoid arthritis (RA) since Hench had attempted to administer cortisone (Kendall's compound E) to an active RA patient in 1948. Rheumatologists even in the 21st c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbde9501aa776d3bbb53fd09a45d7d73
https://doi.org/10.2177/jsci.34.464
https://doi.org/10.2177/jsci.34.464
Autor:
Hideto Akama
Publikováno v:
Japanese Journal of Clinical Immunology. 30:404-407
RANK ligand (RANKL) is a key mediator of osteoclast formation, function, and survival. Therefore, RANKL is thought to be responsible for osteoclast-mediated bone resorption in a broad range of disorders such as postmenopausal osteoporosis and cancer-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e82cbc652cf46b6998130a38d83a7a0
https://doi.org/10.2177/jsci.30.404
https://doi.org/10.2177/jsci.30.404
Autor:
Mika Katagiri, Hatsue Tazaki, Masao Sasamata, Aishi Kimoto, Shun-ichi Harada, Toru Ogasawara, Hiroshi Kawaguchi, Tsuyoshi Takato, Kazuto Hoshi, Daichi Chikazu, Masahiro Noguchi, Kozo Nakamura, Ung-il Chung, Hideto Akama
Publikováno v:
Journal of Bone and Mineral Research. 21:219-227
In vitro assays revealed that COX-2 inhibitors with CA II inhibitory potency suppressed both differentiation and activity of osteoclasts, whereas that without the potency reduced only osteoclast differentiation. However, all COX-2 inhibitors similarl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7126bebc6ce55983f509c0eca003c8c2
https://doi.org/10.1359/jbmr.051025
https://doi.org/10.1359/jbmr.051025